Ampersand Capital Partners Mergers and Acquisitions Summary

Growth Capital Firm Profile

In the last 3 years, Ampersand Capital Partners has acquired 7 companies. It has also invested in 11 others.

Ampersand Capital Partners’ most common sectors for investment arelife science (48%) and medical products (26%) . The Firm’s most common investment types include buyout (lbo, mbo, mbi) (33%) and growth capital (31%). In total, Ampersand Capital Partners has invested in 20 US states and 6 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.

In the last 3 years, Ampersand Capital Partners has exited 11 companies. The Firm’s most common exit type is trade sale (73%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.

Join Mergr to view Ampersand Capital Partners’ full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity103
    • M&A Buy Activity59
    • M&A Sell Activity44
  • Total Sectors Invested 12
  • Total Countries Invested 6
  • M&A Buy/Sell Connections 54
  • M&A Advisors 1

Ampersand Capital Partners

55 William St., Ste. 240,
Wellesley, Massachusetts 02481
United States
(781) 239-0700
www.ampersandcapital.com
info@ampersandcapital.com

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products, Test/Measurement Equipment

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Recapitalization, Secondary Buyout, Stake Purchase, Venture

Geographic Preferences: East US, Midwest US, South US, West US, Canada, United Kingdom, Western Europe, Eastern Europe, Scandinavia

Transaction Criteria Min Max
Target Revenue 10 100
Target EBITDA - -
Investment Size 10 100
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (4.2/yr) # 38 3 6 6 4 2 59
vol $161M $161M
Sell (2.6/yr) # 31 2 6 1 1 3 44
vol $3.7B $828M $1.7B $260M $6.5B
  103

Most Recent M&A

Company Date Value Type
LakePharma, Inc. 2021-07-14 - Add-on Acquisition
San Carlos, California · www.lakepharma.com
Nexcelom Bioscience LLC 2021-05-12 260M USD Add-on Acquisition
Lawrence, Massachusetts · www.nexcelom.com
Magritek 2021-03-18 - Growth Capital
Wellington, New Zealand · www.magritek.com
Bioventus LLC 2021-02-04 - IPO
Durham, North Carolina · www.bioventusglobal.com
Genezen Laboratories, Inc. 2021-01-05 - Growth Capital
Indianapolis, Indiana · www.genezenlabs.com
American Laboratory Products Co. (ALPCO) 2020-09-21 - Recapitalization
Salem, New Hampshire · www.alpco.com
GeneWerk GmbH 2020-09-21 - Growth Capital
Heidelberg, Germany · www.genewerk.com
Canopy Biosciences LLC 2020-09-11 - Add-on Acquisition
St. Louis, Missouri · www.canopybiosciences.com
Tjoapack Netherlands B.V. 2020-04-21 - Buyout (LBO, MBO, MBI)
Etten-Leur, Netherlands · www.tjoapack.com
Interpace Biosciences, Inc. 2020-01-13 - Stake Purchase
Parsippany, New Jersey · www.interpace.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Nexelis 2018-09-04 GlaxoSmithKline plc - The Clinical Laboratory Science 2021-01-20 5
Laval, Quebec · www.nexelis.com Marburg, Germany
Alcami Corp. 2018-06-01 Alcami Corp. - API Facility 2020-10-01 1
Durham, North Carolina · www.alcaminow.com Germantown, Wisconsin

M&A by Sector

Sector Current # Value All-time # Value
Life Science 11 (65%) - 28 (47%) 123M (76%)
Medical Products 3 (18%) 20M (100%) 15 (25%) 38M (24%)
Healthcare Services - - 3 (5%) -
Software 1 (6%) - 3 (5%) -
Chemicals - - 2 (3%) -
Consumer Products - - 2 (3%) -
Consumer Services - - 1 (2%) -
Information Technology - - 1 (2%) -
Manufacturing 1 (6%) - 1 (2%) -
Packaging 1 (6%) - 1 (2%) -
Semiconductors - - 1 (2%) -
Test/Measurement Equipment - - 1 (2%) -
Total 17 $20M 59 $161M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 10 (59%) 20M (100%) 52 (88%) 161M (100%)
  Massachusetts 4 (24%) - 12 (20%) -
  California - - 9 (15%) -
  New Jersey 1 (6%) - 6 (10%) 123M (76%)
  Arizona 1 (6%) 20M (100%) 3 (5%) 20M (12%)
  North Carolina 1 (6%) - 3 (5%) -
  Missouri - - 3 (5%) 18M (11%)
  Indiana 1 (6%) - 2 (3%) -
  Minnesota - - 2 (3%) -
  Virginia 1 (6%) - 1 (2%) -
  New Hampshire 1 (6%) - 1 (2%) -
  Wisconsin - - 1 (2%) -
  Washington - - 1 (2%) -
  Rhode Island - - 1 (2%) -
  Ohio - - 1 (2%) -
  Michigan - - 1 (2%) -
  Maryland - - 1 (2%) -
  Louisiana - - 1 (2%) -
  Georgia - - 1 (2%) -
  Florida - - 1 (2%) -
  Colorado - - 1 (2%) -
Germany 2 (12%) - 2 (3%) -
Netherlands 2 (12%) - 2 (3%) -
United Kingdom 1 (6%) - 1 (2%) -
Canada 1 (6%) - 1 (2%) -
  Quebec 1 (6%) - 1 (2%) -
New Zealand 1 (6%) - 1 (2%) -
Domestic 10 (59%) 20M (100%) 52 (88%) 161M (100%)
Cross-border 7 (41%) - 7 (12%) -
Total 17 $20M 59 $161M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Buyout (LBO, MBO, MBI) 3 (18%) - 19 (32%) -
Growth Capital 8 (47%) 20M (100%) 18 (31%) 20M (12%)
Venture 1 (6%) - 10 (17%) 18M (11%)
Divestiture 1 (6%) - 4 (7%) -
Recapitalization 1 (6%) - 3 (5%) -
Secondary Buyout 2 (12%) - 2 (3%) -
Going Private - - 1 (2%) 123M (76%)
Special Situations/Distressed - - 1 (2%) -
Stake Purchase 1 (6%) - 1 (2%) -
Total 17 $20M 59 $161M

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 18 (41%) 6.3B (98%)
Trade Sale 15 (34%) 127M (2%)
IPO 3 (7%) -
Merger 3 (7%) -
Secondary Sale 3 (7%) -
Recapitalization 1 (2%) -
Unknown 1 (2%) -
Total 44 $6.5B

Top M&A Advisors

Legal Deals
Edwards Wildman Palmer LLP
 1

Deal Values

buy # Total
$100M to $1B 1 $123M
< $100M 2 $38M
TOTAL $161M
Largest BioClinica, Inc.
$123M (2013-03-13)
sell # Total
> $1B 2 $4.8B
$100M to $1B 7 $1.6B
< $100M 2 $76M
TOTAL $6.5B
Largest Talecris Biotherapeutics Holdings Corp
$3.1B (2008-08-12)

M&A Connections

Deals
Acquired from
Investor(s)
3%
2 (3%)
Strategic(s)
7%
4 (7%)
Exited to
Investor(s)
9%
4 (9%)
Strategic(s)
77%
34 (77%)

Investor Summary

Investor Type

Growth Capital Firm

Size

Large

PE Assets

2.0B USD

Established

1988

Specialist/Generalist

Specialist

Leadership

Richard Charpie

Founder & Managing Partner

David Anderson

General Partner

David Parker

General Partner

Eric B.Lev

General Partner

Herbert Hooper

Managing Partner

 Subscribe to unlock this and 169,018
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.2K Private Equity Firms
  • 158K M&A Transactions
  • 165K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.3K M&A Advisors
    (Investment Banks and Law Firms)
  • 57K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal